Trial · NCT07888075
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
NCT07888075, Phase 2, Phase 3, Not yet recruiting, AVEO Pharmaceuticals, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC. Trials, record NCT07888075. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07888075
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
- NCT number
- NCT07888075
- Status
- Not yet recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 950 participants, estimated
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC), Metastatic Non-small Cell Lung Cancer (NSCLC), Weight Loss, Anorexia
- Interventions
- Rilogrotug, Placebo
- First posted
- 2026-10-22
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase 2 (A): To evaluate the effect of rilogrotug compared to placebo on weight gain | 12 weeks | Percent change from baseline in body weight |
| Primary | Phase 2 (A): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale score | 12 weeks | Scale has five items, each rated 0-4. Total score ranges from 0 (minimum) to 20 (maximum). Higher score is associated with a better outcome. |
| Primary | Phase 3 (B): To evaluate the effect of rilogrotug compared to placebo on weight gain | 12 weeks | Percent change from baseline in body weight |
| Primary | Phase 3 (B): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale score | 12 weeks | Scale has five items, each rated 0-4. Total score ranges from 0 (minimum) to 20 (maximum). Higher score is associated with a better outcome. |
| Primary | Phase 3 (C): To evaluate the effect of rilogrotug compared to placebo on weight gain | 12 weeks | Percent change from baseline in body weight |
| Primary | Phase 3 (C): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale score | 12 weeks | Scale has five items, each rated 0-4. Total score ranges from 0 (minimum) to 20 (maximum). Higher score is associated with a better outcome. |
| Primary | OLE (D): To evaluate the safety and tolerability of long-term rilogrotug administration | 52 weeks | Adverse events and Laboratory abnormalities |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07888075
GET https://conductscience.org/api/trials/v1/NCT07888075/registered